Literature DB >> 20581688

The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.

Michelle M Estrella1, Rulan S Parekh, Alison Abraham, Brad C Astor, Lynda A Szczech, Kathryn Anastos, Jack A Dehovitz, Daniel J Merenstein, C Leigh Pearce, Phyllis C Tien, Mardge H Cohen, Stephen J Gange.   

Abstract

BACKGROUND: In the early highly active antiretroviral therapy (HAART) era, kidney dysfunction was strongly associated with death among HIV-infected individuals. We re-examined this association in the later HAART period to determine whether chronic kidney disease remains a predictor of death after HAART initiation.
METHODS: To evaluate the effect of kidney function at the time of HAART initiation on time to all-cause mortality, we evaluated 1415 HIV-infected women initiating HAART in the Women's Interagency HIV Study. Multivariable proportional hazards models with survival times calculated from HAART initiation to death were constructed; participants were censored at the time of the last available visit or December 31, 2006.
RESULTS: Chronic kidney disease (estimated glomerular filtration rate less than 60 mL/min/1.73 m) at HAART initiation was associated with higher mortality risk adjusting for age, race, hepatitis C serostatus, AIDS history, and CD4 cell count (hazard ratio 2.23, 95% confidence interval: 1.45-3.43). Adjustment for hypertension and diabetes history attenuated this association (hazard ratio = 1.89, confidence interval: 0.94-3.80). Lower kidney function at HAART initiation was weakly associated with increased mortality risk in women with prior AIDS (hazard ratio = 1.09, confidence interval: 1.00-1.19, per 20% decrease in estimated glomerular filtration rate).
CONCLUSIONS: Kidney function at HAART initiation remains an independent predictor of death in HIV-infected individuals, especially in those with a history of AIDS. Our study emphasizes the necessity of monitoring kidney function in this population. Additional studies are needed to determine mechanisms underlying the increased mortality risk associated with chronic kidney disease in HIV-infected persons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20581688      PMCID: PMC3243740          DOI: 10.1097/QAI.0b013e3181e674f4

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  15 in total

1.  Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Authors:  Nancy F Crum; Robert H Riffenburgh; Scott Wegner; Brian K Agan; Sybil A Tasker; Katherine M Spooner; Adam W Armstrong; Susan Fraser; Mark R Wallace
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

Review 2.  Chronic kidney disease and mortality risk: a systematic review.

Authors:  Marcello Tonelli; Natasha Wiebe; Bruce Culleton; Andrew House; Chris Rabbat; Mei Fok; Finlay McAlister; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2006-05-31       Impact factor: 10.121

3.  HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.

Authors:  Michelle Estrella; Derek M Fine; Joel E Gallant; M Hafizur Rahman; Nagapradeep Nagajothi; Lorraine C Racusen; Paul J Scheel; Mohamed G Atta
Journal:  Clin Infect Dis       Date:  2006-06-20       Impact factor: 9.079

4.  Determinants of survival among HIV-infected chronic dialysis patients.

Authors:  Rudolph A Rodriguez; Michael Mendelson; Ann M O'Hare; Ling Chin Hsu; Patricia Schoenfeld
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

5.  Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.

Authors:  Paul Muntner; Jiang He; Lee Hamm; Catherine Loria; Paul K Whelton
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

6.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

7.  Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy.

Authors:  Lynda Anne Szczech; Donald R Hoover; Joseph G Feldman; Mardge H Cohen; Stephen J Gange; Lisa Goozé; Nancy R Rubin; Mary A Young; Xiaotao Cai; Qiuhu Shi; Wei Gao; Kathryn Anastos
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

8.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

9.  From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  JAMA       Date:  1993-02-10       Impact factor: 56.272

10.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy.

Authors:  Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

View more
  25 in total

Review 1.  Renal disease in HIV-infected individuals.

Authors:  John Phair; Frank Palella
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

Review 2.  Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010.

Authors:  James D Neaton; Jacqueline Neuhaus; Sean Emery
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

3.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Authors:  Pedro Rodríguez Quesada; Laura López Esteban; Jimena Ramón García; Rocío Vázquez Sánchez; Teresa Molina García; Gabriel Gaspar Alonso-Vega; Javier Sánchez-Rubio Ferrández
Journal:  Int J Clin Pharm       Date:  2015-05-26

4.  Markers of renal disease and function are associated with systemic inflammation in HIV infection.

Authors:  S K Gupta; D Kitch; C Tierney; K Melbourne; B Ha; G A McComsey
Journal:  HIV Med       Date:  2015-05-20       Impact factor: 3.180

5.  Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa.

Authors:  Michelle M Estrella; Mohammed R Moosa; Jean B Nachega
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

Review 6.  Renal issues in HIV infection.

Authors:  Robert C Kalayjian
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

7.  Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women.

Authors:  Michelle M Estrella; Alison G Abraham; Yuezhou Jing; Rulan S Parekh; Phyllis C Tien; Dan Merenstein; Celeste Leigh Pearce; Kathryn Anastos; Mardge H Cohen; Jack A Dehovitz; Stephen J Gange
Journal:  AIDS Res Hum Retroviruses       Date:  2013-01-29       Impact factor: 2.205

8.  Recurrent HIV-associated immune complex glomerulonephritis with lupus-like features after kidney transplantation.

Authors:  Sindhu Chandran; Kuang-Yu Jen; Zoltan G Laszik
Journal:  Am J Kidney Dis       Date:  2013-03-05       Impact factor: 8.860

Review 9.  Update on cystatin C: incorporation into clinical practice.

Authors:  Michael G Shlipak; Monica D Mattes; Carmen A Peralta
Journal:  Am J Kidney Dis       Date:  2013-05-20       Impact factor: 8.860

10.  Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.

Authors:  M Hentzien; M Dramé; C Allavena; C Jacomet; M-A Valantin; A Cabié; L Cuzin; D Rey; P Pugliese; F Bani-Sadr
Journal:  J Nutr Health Aging       Date:  2016-04       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.